Fig. 6: In vivo efficacy of the VEGF-PDGF DutaFab.
From: DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously
The in vivo efficacy of the most potent bispecific DutaFab against VEGFA and PDGF-BB, clone VP mat YHE, was analyzed using a laser-induced choroidal neovascularization (LCNV) model performed in pigmented Brown Norway rats. Each data point shown represents the average fluorescence angiography (FA) score for the lesions in one eye 6 days post laser treatment. a Result for antibody treatment by a single intravitreal administration on the day of laser induction. b Result for antibody treatment by a single intravitreal administration three days before laser induction. Sample size was n = 7 for anti-DIG, n = 16 for anti-VEGF_A and n = 14 for VP mat YHE. The whiskers represent the range from the lowest to the highest value in the set; the horizontal line within each box represents the median; boxes range from the 25th to the 75th percentile. Numbers over brackets represent adjusted p-values obtained from one-way ANOVA followed by the Holm–Šídák multiple comparison method.
